Laura Francis Sells 51,884 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 51,884 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64. Following the sale, the chief executive officer directly owned 321,386 shares of the company’s stock, valued at approximately $6,254,171.56. This trade represents a 13.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.

SiBone Trading Up 2.5%

NASDAQ:SIBN opened at $19.96 on Friday. The business’s 50-day moving average is $17.49 and its two-hundred day moving average is $15.33. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89. The firm has a market capitalization of $885.23 million, a PE ratio of -58.71 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The company had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. Research analysts predict that SiBone will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of SiBone

Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada lifted its stake in shares of SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares in the last quarter. Versant Capital Management Inc boosted its holdings in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares in the last quarter. Larson Financial Group LLC grew its stake in SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after purchasing an additional 1,061 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock valued at $733,000 after purchasing an additional 1,459 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SIBN shares. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. UBS Group lifted their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. TD Cowen boosted their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Truist Financial restated a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.17.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.